ID

12357

Description

Study description: Study documentation part- Study termination. This is a phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS). Principal Investigator PD Dr. Tobias Grge, University Hospital of Mnster. EudraCT - Nr. 2012-000108-13.

Keywords

  1. 11/11/15 11/11/15 -
Uploaded on

November 11, 2015

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Riliva_CRF_EudraCT - Nr. 2012-000108-13-Study termination DRKS00004652

Riliva_CRF_EudraCT - Nr. 2012-000108-13-Study termination

Studienabbruch
Description

Studienabbruch

Alias
UMLS CUI-1
C0008972
UMLS CUI-2
C0013135
Datum des Studienabbruchs:
Description

date

Data type

date

Zentrum Nr.:
Description

Center number

Data type

integer

Primärer Grund für Studienabbruch:
Description

Study termination; reason

Data type

text

Alias
UMLS CUI [1,1]
C0008972
UMLS CUI [1,2]
C0013135
UMLS CUI [1,3]
C1272707
Bitte die verletzten Kriterium erläutern:
Description

inclusion criteria; exclusion criteria

Data type

text

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251

Similar models

Riliva_CRF_EudraCT - Nr. 2012-000108-13-Study termination

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Studienabbruch
C0008972 (UMLS CUI-1)
C0013135 (UMLS CUI-2)
date
Item
Datum des Studienabbruchs:
date
Center number
Item
Zentrum Nr.:
integer
Item
Primärer Grund für Studienabbruch:
text
C0008972 (UMLS CUI [1,1])
C0013135 (UMLS CUI [1,2])
C1272707 (UMLS CUI [1,3])
Code List
Primärer Grund für Studienabbruch:
CL Item
Widerruf der Einwilligungserklärung durch Patient (1)
CL Item
Vorzeitiges Schließen der gesamten Studie (2)
CL Item
Mangelnde Compliance des Patienten  (3)
CL Item
Abfall des Hämoglobin Wertes von über 2 Einheiten [g/dl] vom Ausgangswert und Blutungsquelle kann nicht gestoppt werden (4)
CL Item
Entscheidung des Prüfarztes, dass eine weitere Teilnahme des Patienten an der Studie nicht vertretbar ist (5)
CL Item
Verletzung von Ein- bzw. Ausschlusskriterien nach 1. Gabe Prüfmedikation (6)
inclusion criteria; exclusion criteria
Item
Bitte die verletzten Kriterium erläutern:
text
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial